BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, Cartenì M. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol. 2002;97:2144-2146. [PMID: 12190198 DOI: 10.1111/j.1572-0241.2002.05942.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 86] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Poordad FF. Nonalcoholic fatty liver disease: a review. Expert Opinion on Emerging Drugs 2005;10:661-70. [DOI: 10.1517/14728214.10.3.661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15518-15531. [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 76] [Article Influence: 14.3] [Reference Citation Analysis]
3 Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T. Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol. 2009;51:168-175. [PMID: 19446916 DOI: 10.1016/j.jhep.2009.02.032] [Cited by in Crossref: 107] [Cited by in F6Publishing: 109] [Article Influence: 8.9] [Reference Citation Analysis]
4 Nardone G, Rocco A. Probiotics: a potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol. 2004;38:S121-S122. [PMID: 15220676 DOI: 10.1097/01.mcg.0000128934.53920.1d] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
5 Budick-Harmelin N, Dudas J, Demuth J, Madar Z, Ramadori G, Tirosh O. Triglycerides potentiate the inflammatory response in rat Kupffer cells. Antioxid Redox Signal. 2008;10:2009-2022. [PMID: 18710323 DOI: 10.1089/ars.2007.1876] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
6 D'Argenio G, Cariello R, Tuccillo C, Mazzone G, Federico A, Funaro A, De Magistris L, Grossi E, Callegari ML, Chirico M. Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage? Liver Int. 2013;33:687-697. [PMID: 23448378 DOI: 10.1111/liv.12117] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
7 Lasker S, Rahman MM, Parvez F, Zamila M, Miah P, Nahar K, Kabir F, Sharmin SB, Subhan N, Ahsan GU, Alam MA. High-fat diet-induced metabolic syndrome and oxidative stress in obese rats are ameliorated by yogurt supplementation. Sci Rep 2019;9:20026. [PMID: 31882854 DOI: 10.1038/s41598-019-56538-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 21.5] [Reference Citation Analysis]
8 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
9 Kirsch R, Clarkson V, Verdonk RC, Marais AD, Shephard EG, Ryffel B, De La M Hall P. Rodent nutritional model of steatohepatitis: Effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. Journal of Gastroenterology and Hepatology 2006;21:174-82. [DOI: 10.1111/j.1440-1746.2005.04220.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
10 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20:12956-12980. [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 82] [Article Influence: 17.3] [Reference Citation Analysis]
11 Vitetta L, Manuel R, Zhou JY, Linnane AW, Hall S, Coulson S. The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures. Pharmaceuticals (Basel) 2014;7:954-89. [PMID: 25244509 DOI: 10.3390/ph7090954] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
12 Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver diseases. World J Gastroenterol. 2010;16:403-410. [PMID: 20101763 DOI: 10.3748/wjg.v16.i4.403] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 57] [Article Influence: 6.4] [Reference Citation Analysis]
13 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
14 Cariello R, Federico A, Sapone A, Tuccillo C, Scialdone VR, Tiso A, Miranda A, Portincasa P, Carbonara V, Palasciano G. Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. Dig Liver Dis. 2010;42:200-204. [PMID: 19502117 DOI: 10.1016/j.dld.2009.05.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
15 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
16 Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol. 2008;49:821-830. [PMID: 18674841 DOI: 10.1016/j.jhep.2008.05.025] [Cited by in Crossref: 254] [Cited by in F6Publishing: 220] [Article Influence: 19.5] [Reference Citation Analysis]
17 Imani Fooladi AA, Mahmoodzadeh Hosseini H, Nourani MR, Khani S, Alavian SM. Probiotic as a novel treatment strategy against liver disease. Hepat Mon. 2013;13:e7521. [PMID: 23610585 DOI: 10.5812/hepatmon.7521] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
18 Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2012;30:149-73. [PMID: 22224779 DOI: 10.1146/annurev-immunol-020711-075001] [Cited by in Crossref: 236] [Cited by in F6Publishing: 219] [Article Influence: 26.2] [Reference Citation Analysis]
19 Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol. 2008;42 Suppl 2:S80-S84. [PMID: 18542037 DOI: 10.1097/mcg.0b013e318169c44e] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
20 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
21 Nardone G, Compare D, Liguori E, Di Mauro V, Rocco A, Barone M, Napoli A, Lapi D, Iovene MR, Colantuoni A. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. American Journal of Physiology-Gastrointestinal and Liver Physiology 2010;299:G669-76. [DOI: 10.1152/ajpgi.00188.2010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
22 Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011;3:637-682. [PMID: 22254115 DOI: 10.3390/nu3060637] [Cited by in Crossref: 217] [Cited by in F6Publishing: 181] [Article Influence: 21.7] [Reference Citation Analysis]
23 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 10.8] [Reference Citation Analysis]
24 Machado MV, Cortez-pinto H. Gut microbiota and nonalcoholic fatty liver disease. Annals of Hepatology 2012;11:440-9. [DOI: 10.1016/s1665-2681(19)31457-7] [Cited by in Crossref: 99] [Article Influence: 11.0] [Reference Citation Analysis]
25 Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD005165. [PMID: 17253543 DOI: 10.1002/14651858.CD005165.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
26 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
27 Arasaradnam RP, McFarlane M, Ling K, Wurie S, O'Connell N, Nwokolo CU, Bardhan KD, Skinner J, Savage RS, Covington JA. Breathomics--exhaled volatile organic compound analysis to detect hepatic encephalopathy: A pilot study. J Breath Res. 2016;10:016012. [PMID: 26866470 DOI: 10.1088/1752-7155/10/1/016012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
28 Nobili V, Sanyal AJ. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol 2012;47:29-36. [PMID: 21983927 DOI: 10.1007/s00535-011-0467-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Mohammadmoradi S, Javidan A, Kordi J. Boom of probiotics: This time non-alcoholic fatty liver disease – A mini review. Journal of Functional Foods 2014;11:30-5. [DOI: 10.1016/j.jff.2014.08.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
30 McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012;112:401-409. [PMID: 22717200 DOI: 10.1016/j.jada.2011.10.007] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 10.1] [Reference Citation Analysis]
31 Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003;38:681-687. [PMID: 12713883 DOI: 10.1016/s0168-8278(03)00097-7] [Cited by in Crossref: 124] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
32 Chávez-tapia NC, González-rodríguez L, Jeong M, López-ramírez Y, Barbero-becerra V, Juárez-hernández E, Romero-flores JL, Arrese M, Méndez-sánchez N, Uribe M. Current evidence on the use of probiotics in liver diseases. Journal of Functional Foods 2015;17:137-51. [DOI: 10.1016/j.jff.2015.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
33 Lenoir-Wijnkoop I, Sanders ME, Cabana MD, Caglar E, Corthier G, Rayes N, Sherman PM, Timmerman HM, Vaneechoutte M, Van Loo J, Wolvers DA. Probiotic and prebiotic influence beyond the intestinal tract. Nutr Rev 2007;65:469-89. [PMID: 18038940 DOI: 10.1111/j.1753-4887.2007.tb00272.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
34 Ma X, Li Z. Pathogenesis of nonalcoholic steatohepatitis (NASH). Chin Dig Dis 2006;7:7-11. [DOI: 10.1111/j.1443-9573.2006.00237.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
35 Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci 2014;97:7386-93. [PMID: 25306266 DOI: 10.3168/jds.2014-8500] [Cited by in Crossref: 99] [Cited by in F6Publishing: 79] [Article Influence: 14.1] [Reference Citation Analysis]
36 Vitetta L, Palacios T, Hall S, Coulson S. Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology. Prog Drug Res 2015;70:1-33. [PMID: 26462363 DOI: 10.1007/978-3-0348-0927-6_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Baratta F, Pastori D, Bartimoccia S, Cammisotto V, Cocomello N, Colantoni A, Nocella C, Carnevale R, Ferro D, Angelico F, Violi F, Del Ben M. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E1732. [PMID: 32531941 DOI: 10.3390/nu12061732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
38 Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
39 Pan X, Wen SW, Kaminga AC, Liu A. Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Sci Rep 2020;10:8848. [PMID: 32483129 DOI: 10.1038/s41598-020-65051-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
40 Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, Irwin C. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr 2018;57:2037-53. [PMID: 29119235 DOI: 10.1007/s00394-017-1568-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
41 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708. [PMID: 20955971 DOI: 10.1016/j.bpg.2010.08.005] [Cited by in Crossref: 128] [Cited by in F6Publishing: 104] [Article Influence: 12.8] [Reference Citation Analysis]
42 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 9.2] [Reference Citation Analysis]
43 Xia D, Yang L, Li Y, Chen J, Zhang X, Wang H, Zhai S, Jiang X, Meca G, Wang S, Huang L, Zhu S, Fu Y, Ma W, Zhu Y, Ye H, Wang W. Melatonin alleviates Ochratoxin A-induced liver inflammation involved intestinal microbiota homeostasis and microbiota-independent manner. J Hazard Mater 2021;413:125239. [PMID: 33582472 DOI: 10.1016/j.jhazmat.2021.125239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;CD008716. [PMID: 22071855 DOI: 10.1002/14651858.cd008716.pub2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
45 Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: Probiotics as a novel therapy. Hepatobiliary Surg Nutr. 2018;7:11-20. [PMID: 29531939 DOI: 10.21037/hbsn.2017.12.07] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
46 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56:461-468. [PMID: 23287807 DOI: 10.1016/j.numecd.2012.02.007] [Cited by in Crossref: 229] [Cited by in F6Publishing: 216] [Article Influence: 28.6] [Reference Citation Analysis]
47 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
48 Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res. 2016;167:116-124. [PMID: 26318867 DOI: 10.1016/j.trsl.2015.08.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
49 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013;56:461-8. [PMID: 23287807 DOI: 10.1097/MPG.0b013e318284abb5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 52] [Article Influence: 14.6] [Reference Citation Analysis]
50 Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540-543. [PMID: 15942443 DOI: 10.1097/01.mcg.0000165671.25272.0f] [Cited by in Crossref: 297] [Cited by in F6Publishing: 275] [Article Influence: 18.6] [Reference Citation Analysis]
51 Sajjad A, Mottershead M, Syn WK, Jones R, Smith S, Nwokolo CU. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;22:291-299. [PMID: 16097995 DOI: 10.1111/j.1365-2036.2005.02562.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
52 Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. Annals of Hepatology 2013;12:357-63. [DOI: 10.1016/s1665-2681(19)30997-4] [Cited by in Crossref: 24] [Article Influence: 3.0] [Reference Citation Analysis]
53 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
54 Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-49. [PMID: 17845148 DOI: 10.1517/14728222.11.9.1231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
55 Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691-701. [PMID: 21045794 DOI: 10.1038/nrgastro.2010.172] [Cited by in Crossref: 298] [Cited by in F6Publishing: 258] [Article Influence: 27.1] [Reference Citation Analysis]
56 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
57 Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem. 2005;38:203-217. [PMID: 15708540 DOI: 10.1016/j.clinbiochem.2004.10.014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
58 Li F, McClain CJ, Feng W. Microbiome dysbiosis and alcoholic liver disease. Liver Res 2019;3:218-26. [PMID: 33868760 DOI: 10.1016/j.livres.2019.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
59 Scotti E, Boué S, Sasso GL, Zanetti F, Belcastro V, Poussin C, Sierro N, Battey J, Gimalac A, Ivanov NV, Hoeng J. Exploring the microbiome in health and disease: Implications for toxicology. Toxicology Research and Application 2017;1:239784731774188. [DOI: 10.1177/2397847317741884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
60 Sato Y. Encounter with childbirth in a sitting position. Josanpu Zasshi. 1985;39:802-803. [PMID: 3854811 DOI: 10.7812/tpp/12-144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
61 Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130:S78-S90. [PMID: 16473077 DOI: 10.1053/j.gastro.2005.11.046] [Cited by in Crossref: 213] [Cited by in F6Publishing: 163] [Article Influence: 14.2] [Reference Citation Analysis]
62 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
63 Houghton D, Stewart CJ, Day CP, Trenell M. Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci. 2016;17:447. [PMID: 27023533 DOI: 10.3390/ijms17040447] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
64 Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco C, Loguercio C. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011;43:431-438. [PMID: 21163715 DOI: 10.1016/j.dld.2010.10.015] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 9.5] [Reference Citation Analysis]
65 Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 2017;38:231-40. [DOI: 10.1093/carcin/bgx007] [Cited by in Crossref: 104] [Cited by in F6Publishing: 44] [Article Influence: 26.0] [Reference Citation Analysis]
66 Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol. 2012;303:G32-G41. [PMID: 22538402 DOI: 10.1080/07315724.2012.10720004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
67 Fang TJ, Guo JT, Lin MK, Lee MS, Chen YL, Lin WH. Protective effects of Lactobacillus plantarum against chronic alcohol-induced liver injury in the murine model. Appl Microbiol Biotechnol 2019;103:8597-608. [PMID: 31515596 DOI: 10.1007/s00253-019-10122-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Manco M, Putignani L, Bottazzo GF. Gut Microbiota, Lipopolysaccharides, and Innate Immunity in the Pathogenesis of Obesity and Cardiovascular Risk. Endocrine Reviews 2010;31:817-44. [DOI: 10.1210/er.2009-0030] [Cited by in Crossref: 268] [Cited by in F6Publishing: 245] [Article Influence: 24.4] [Reference Citation Analysis]
70 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:1756-67. [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
71 Zhao Z, Wang C, Zhang L, Zhao Y, Duan C, Zhang X, Gao L, Li S. Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway. Appl Microbiol Biotechnol 2019;103:5843-50. [DOI: 10.1007/s00253-019-09703-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
72 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
73 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
74 Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711. [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 109] [Article Influence: 11.3] [Reference Citation Analysis]
75 Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343-350. [PMID: 12540784 DOI: 10.1053/jhep.2003.50048] [Cited by in Crossref: 613] [Cited by in F6Publishing: 570] [Article Influence: 34.1] [Reference Citation Analysis]
76 Federico A, Trappoliere M, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig Liver Dis. 2006;38:789-801. [PMID: 16750661 DOI: 10.1016/j.dld.2006.04.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
77 Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr. 2009;139:905-911. [PMID: 19321579 DOI: 10.3945/jn.108.101808] [Cited by in Crossref: 149] [Cited by in F6Publishing: 138] [Article Influence: 12.4] [Reference Citation Analysis]
78 Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int J Prev Med 2016;7:59. [PMID: 27076897 DOI: 10.4103/2008-7802.178533] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
79 Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 94] [Article Influence: 24.2] [Reference Citation Analysis]
80 Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2014;5:403-23. [DOI: 10.1586/eem.10.5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
81 Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 2014;15:2501-11. [DOI: 10.1517/14656566.2014.960389] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
82 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
83 Donnadieu-Rigole H, Pansu N, Mura T, Pelletier S, Alarcon R, Gamon L, Perney P, Apparailly F, Lavigne JP, Dunyach-Remy C. Beneficial Effect of Alcohol Withdrawal on Gut Permeability and Microbial Translocation in Patients with Alcohol Use Disorder. Alcohol Clin Exp Res 2018;42:32-40. [PMID: 29030980 DOI: 10.1111/acer.13527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
84 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
85 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
86 Li F, Duan K, Wang C, McClain C, Feng W. Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms. Gastroenterol Res Pract 2016;2016:5491465. [PMID: 26839540 DOI: 10.1155/2016/5491465] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]